Liquid biopsy trial aims to personalize GI cancer care

NCT ID NCT06202131

Recruiting now Knowledge-focused Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is testing whether measuring ctDNA (bits of tumor DNA) in blood or stool can help doctors manage patients with cancers of the digestive tract, including pancreas, colon, and bile duct cancers. Researchers will track survival and see how these markers relate to outcomes. The goal is to learn if this non-invasive test can guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could show that a simple blood or stool test helps doctors better predict survival and tailor treatment for gastrointestinal cancers.
What could go wrong: This is an early, single-center study with only 100 people. It is observational, so it won't directly test a new treatment. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms colon carcinoma colonic neoplasm esophageal cancer gastric cancer intestinal cancer malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER COLON CANCER PANCREAS CANCER

Contacts and locations

Locations

Policlinico Agostino Gemelli
RECRUITING

Rome, Lazio, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.